Compliance with treatment for osteoporosis

Lancet

Volumn 368, Issue 9548, 2006, Pages 1648-

  Cooper, Alun ^a  

^a Bridge Medical Centre   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; IBANDRONIC ACID;

CLINICAL PROTOCOL; FOLLOW UP; FRAGILITY FRACTURE; HUMAN; LETTER; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; PRESCRIPTION; PRIORITY JOURNAL; RISK REDUCTION; TREATMENT OUTCOME;

EID: 33846068686     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(06)69691-8     Document Type: Letter

References (2)

1. Compston J., and Seeman E. Compliance with osteoporosis therapy is the weakest link. Lancet 368 (2006) 973-974
2. Cooper A., Drake J., and Brankin E. Treatment persistence with once-monthly ibandronate and patient support vs once-weekly alendronate. Int J Clin Prac 60 (2006) 896-905